



EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY'S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL

M. J. Cumbraos Sánchez^{1,2}, A. Larrabeiti-Etxebarria^{1,2}, M. M. Mediavilla García^{1,2}, C. Blanco García^{1,2}, A. López de Torre Querejazu^{1,2}, O. Urbina Bengoa^{1,2}, M. D. Martínez García^{1,2}

1. Araba University Hospital, Pharmacy Department, Vitoria-Gasteiz, Spain

2. Bioaraba Health Research Institute

Background


Constipation is a common complication during hospitalization due to the presence of risk factors such as bed rest, diseases causing reduced bowel motility or administration of medications (opioids, anticholinergic drugs...). The **standard therapy is laxative drugs**.

Murphy's enema (ME) is used for the treatment of constipation and fecal impaction **when patients do not respond to laxatives**. It consists of administering an **evacuating solution through a rectal probe during 6 hours** (53 drops/min), leading to a softening of the stool and osmotic evacuation.

Composition of evacuating solution:

Milk	300 ml
Liquid Vaseline	100 ml
Oxygenated water	200 ml
Saline solution	500 ml

Rate of administration: 53 drops/min



Objective

To assess the **effectiveness and safety of ME** for the treatment of constipation and fecal impaction.

Methods

DESIGN

Descriptive, retrospective study

AIM

Effectiveness and safety of Murphy's enema

PATIENTS

Received ME from June 2020 to August 2022

DATA

-Comorbidities
-Defecation achievement
- Indication
-Adverse events

DATA ANALYSIS

Results




N = 33


♂ 15 men
♀ 18 women

Mean age: 76 years old


MOST COMMON COMORBIDITIES



EFFECTIVENESS



INDICATION



ADVERSE EVENTS

- 1 case of hypotension
- 1 case of nausea
- 1 case of abdominal pain

Conclusion

ME constitutes a **safe and effective alternative for patients with constipation and fecal impaction not responding to the usual therapies**. There is no published evidence regarding this practice, so this study may constitute a starting point for the development of further studies with larger sample sizes.

- ATC code: A06 – DRUGS FOR CONSTIPATION
- Poster number: 6ER – 014
- Contact: mariajose.cumbraosanchez@osakidetza.eus



Osakidetza

ARABAKO UNIBERTSITATE OSPITALEA
HOSPITAL UNIVERSITARIO ARABA

bioaraba

osasun ikerketa institutua
instituto de investigación sanitaria

